Here are the 10-Q quarterly reports from Kailera Therapeutics, Inc. (KLRA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow KLRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLRA filings page.
Kailera Therapeutics, Inc., a clinical-stage obesity-focused biotechnology company, reported a larger loss as it ramped R&D and completed its IPO. For the quarter ended June 30, 2026, net loss was $111.3 million, driven by research and development expenses of $101.1 million and general and administrative expenses of $20.3 million. For the first six months of 2026, net loss totaled $190.2 million.
Following its April 20, 2026 initial public offering, which raised $662.0 million in net proceeds, total assets grew to $1.21 billion with cash, cash equivalents and marketable securities of $1,171.8 million as of June 30, 2026. Management states this liquidity is sufficient to fund operations and capital needs for at least twelve months from issuance of the financial statements and into mid‑2028. Kailera remains pre-revenue and continues to advance four GLP‑1–based obesity programs, including lead candidate ribupatide injection now in global Phase 3 trials, under an exclusive license and collaboration with Hengrui.
Kailera Therapeutics, Inc. reported a net loss of $78.9 million for the three months ended March 31, 2026, significantly higher than $18.0 million a year earlier as it ramped spending on obesity drug development.
Research and development expenses rose to $70.9 million, up from $10.1 million, driven by global Phase 3 trials for ribupatide injection and advancement of its oral GLP-1 programs. General and administrative costs increased to $13.8 million.
At March 31, 2026, Kailera held $581.9 million in cash, cash equivalents and marketable securities. Including $718.8 million of gross proceeds from its April 2026 IPO, the company believes it is funded into mid-2028 while progressing four clinical-stage obesity product candidates, supported by recent positive data from KAI-7535 and KAI-4729.